SenesTech reports preliminary third-quarter revenue of about $1.1 million

Key Facts

SenesTech announced preliminary revenue of nearly $1.1 million for the third quarter of 2026, according to the earnings release attached to its filing with the U.S. Securities and Exchange Commission. Quarterly revenue thus exceeded the million-dollar threshold for the first time in the history of the rodent fertility control products company. Revenue rose about 40% from the second quarter of 2026, posting sequential growth alongside the annual increase. Growth from the third quarter of 2025 was about 55%, according to the comparison the company provided in its preliminary performance release. The revenue figures remain unaudited and subject to adjustment as the company completes its customary financial reporting and quarter-end closing procedures.

SenesTech attributed its sales trajectory to continued e-commerce momentum, which it said it expects to be reflected in its final third-quarter results. This activity included higher subscription revenue, which the company said expands the recurring component of its revenue base, alongside improved business-to-business sales activity. On costs, Chief Executive Michael Eidel said many of the investments and transition costs incurred earlier in the year were now easing. Eidel linked this development to revenue growth and improving unit economics in his account of the operating trajectory accompanying the preliminary figures. He described the operational improvement as including "strong revenue growth and improving unit economics," according to his comments in the company release.

In the background, an earlier ownership filing by Glenbrook Capital Management in July 2026 disclosed a 19.95% stake in SenesTech. The filing outlined a broad range of topics for Glenbrook's discussions with the company's management, board and shareholders, including its business, operations, marketing and overall strategy. Topics listed under the purpose of the investment also extended to capital structure and governance, according to the document filed with the U.S. Securities and Exchange Commission. Glenbrook disclosed in the same filing that it had provided funds to marketing or branding consultants to offer strategic advice on certain SenesTech products. The move places Glenbrook's earlier involvement in products and marketing alongside the corporate and financial topics covered in its discussions with company stakeholders.

The July filing was preceded by Glenbrook purchases of SenesTech shares during the year, including a March transaction covered by Investing.com. On March 13, 2026, Glenbrook purchased 146249 shares at $1.9517 per share, according to transaction details published by the website. In separate coverage published in June 2026, the website reported additional Glenbrook purchases of company shares and listed its holdings following the transactions covered in the report. Those indirect holdings totaled 962,408 shares of SenesTech common stock, according to the coverage tracking the purchases at the time. The disclosed 19.95% ownership stake comes from the subsequent July filing, while the share counts and purchase prices cited relate to the March purchases and June coverage.

As for previous financial results, SenesTech reported that its net loss narrowed to $1.8 million in the second quarter of 2026. The company compared this with a net loss of $2.1 million in the first quarter of the same year, according to the earnings release attached to its filing with the U.S. regulator. That improvement in losses preceded the preliminary third-quarter revenue announcement, which addressed sales growth and related operational developments. In trading following the second-quarter results, Investing.com coverage published in August 2026 reported that the company's shares fell after the market close. The decline at the time was 23.31% to $1.25 per share, following the announcement of that quarter's results.

SenesTech develops the rodent fertility control products "Evolve" and "ContraPest" as part of a business aimed at reducing rodent populations by affecting their reproduction. The company also provides assessment and monitoring services alongside these products, according to the description of its business in the preliminary results release. The commercial performance it outlined for the third quarter is tied to e-commerce, subscriptions and business-to-business sales, activities whose effects it said it expects to see in its final results. The company will complete its customary quarterly closing and financial reporting procedures before releasing those results, with preliminary revenue figures remaining subject to adjustment. SenesTech plans to announce its final third-quarter financial results during the week beginning November 9, 2026, according to the schedule set out in its release.